PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 15365622-10 2004 HbA1c and angiotensin II increased during treatment with spironolactone by 0.26+/-0.07% (p=0.001) and 8.12+/-1.94 pg/ml (p=0.001) respectively. Spironolactone 57-71 angiotensinogen Homo sapiens 10-24 15365622-12 2004 These findings are possibly due to the worsening of glycaemic control and increase in plasma angiotensin II that were seen with spironolactone treatment. Spironolactone 128-142 angiotensinogen Homo sapiens 93-107 11836266-5 2002 Angiotensin II increased from baseline during both HCTZ (P = 0.02) and spironolactone (P = 0.02 vs. baseline; P = 0.19 vs. HCTZ) treatments. Spironolactone 71-85 angiotensinogen Homo sapiens 0-14 15159288-8 2004 Preincubating the cells with the MR blocker spironolactone (10(-6) mol/L) abolished Ang II-induced ROS generation, EGFR transactivation, and ERK1/2 phosphorylation. Spironolactone 44-58 angiotensinogen Homo sapiens 84-90 12427411-7 2002 Angiotensin II increased significantly in the spironolactone group at three and six months (p = 0.003 and p = 0.001, respectively). Spironolactone 46-60 angiotensinogen Homo sapiens 0-14 12427411-9 2002 CONCLUSIONS: Spironolactone administration in patients with CHF has opposite effects on circulating levels of natriuretic peptides (which decrease) and aldosterone and AII (which increase). Spironolactone 13-27 angiotensinogen Homo sapiens 168-171 16228919-9 2000 There is an interplay between angiotensin II, aldosterone and the sympathetic nervous system, and thus RAAS antagonists, such as angiotensin converting enzyme inhibitors and spironolactone could directly reduce sympathetic activation. Spironolactone 174-188 angiotensinogen Homo sapiens 30-44 10673249-0 2000 Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Spironolactone 0-14 angiotensinogen Homo sapiens 121-134 10673249-0 2000 Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Spironolactone 0-14 angiotensinogen Homo sapiens 135-149 10634408-9 2000 The time course of the effect of aldosterone on Ang II-induced PAI-1 expression was consistent with a classical mineralocorticoid receptor mechanism, and the effect of aldosterone on PAI-1 synthesis was attenuated by spironolactone. Spironolactone 217-231 angiotensinogen Homo sapiens 48-54 8422004-7 1993 Spironolactone administration caused the curve expressing the relation between an infused norepinephrine or angiotensin II dose and the blood pressure response to shift significantly (p < 0.05 to < 0.01) to the right, and the pressor doses of norepinephrine or angiotensin II showed a significant (p < 0.05 to < 0.01) dose-related increase, suggesting that treatment with spironolactone inhibited cardiovascular reactivity. Spironolactone 0-14 angiotensinogen Homo sapiens 108-122 8422004-7 1993 Spironolactone administration caused the curve expressing the relation between an infused norepinephrine or angiotensin II dose and the blood pressure response to shift significantly (p < 0.05 to < 0.01) to the right, and the pressor doses of norepinephrine or angiotensin II showed a significant (p < 0.05 to < 0.01) dose-related increase, suggesting that treatment with spironolactone inhibited cardiovascular reactivity. Spironolactone 0-14 angiotensinogen Homo sapiens 90-122 8422004-7 1993 Spironolactone administration caused the curve expressing the relation between an infused norepinephrine or angiotensin II dose and the blood pressure response to shift significantly (p < 0.05 to < 0.01) to the right, and the pressor doses of norepinephrine or angiotensin II showed a significant (p < 0.05 to < 0.01) dose-related increase, suggesting that treatment with spironolactone inhibited cardiovascular reactivity. Spironolactone 384-398 angiotensinogen Homo sapiens 108-122 8422004-7 1993 Spironolactone administration caused the curve expressing the relation between an infused norepinephrine or angiotensin II dose and the blood pressure response to shift significantly (p < 0.05 to < 0.01) to the right, and the pressor doses of norepinephrine or angiotensin II showed a significant (p < 0.05 to < 0.01) dose-related increase, suggesting that treatment with spironolactone inhibited cardiovascular reactivity. Spironolactone 384-398 angiotensinogen Homo sapiens 90-122 6386025-8 1984 The slope of the regression of aldosterone on angiotensin II during spironolactone treatment was less than that with amiloride, consistent with partial blockade of aldosterone synthesis by spironolactone. Spironolactone 68-82 angiotensinogen Homo sapiens 46-60 34480296-9 2021 RESULTS: The PI3K/AKT pathway was significantly related to one PCOS subnetwork and most drugs (metformin, letrozole, pioglitazone, and spironolactone); moreover, VEGF, EGF, TGFB1, AGT, AMBP, and RBP4 were identified as the shared proteins between the PCOS subnetwork and the drugs. Spironolactone 135-149 angiotensinogen Homo sapiens 180-183 34076288-7 2021 In RFA combined with spironolactone treatment, spironolactone can directly antagonize the effects of ALD and AngII and the recurrence of AF and improve left ventricular function. Spironolactone 47-61 angiotensinogen Homo sapiens 109-114 6086794-11 1984 Therefore, studies of aldosterone-producing adenomas in vitro should consider the possible effects of preoperative treatment with spironolactone on the responsiveness of the adenomas to angiotensin II and ACTH. Spironolactone 130-144 angiotensinogen Homo sapiens 186-200 34076288-1 2021 At present, the question of whether radiofrequency ablation (RFA) combined with spironolactone can reduce the levels of plasma angiotensin II (AngII) and aldosterone (ALD) in patients with atrial fibrillation (AF) and reduce the recurrence of AF has not been reported. Spironolactone 80-94 angiotensinogen Homo sapiens 127-141 34076288-1 2021 At present, the question of whether radiofrequency ablation (RFA) combined with spironolactone can reduce the levels of plasma angiotensin II (AngII) and aldosterone (ALD) in patients with atrial fibrillation (AF) and reduce the recurrence of AF has not been reported. Spironolactone 80-94 angiotensinogen Homo sapiens 143-148 6086794-7 1984 Adenoma tissue from a patient given spironolactone for 4 days was responsive to angiotensin II and to ACTH. Spironolactone 36-50 angiotensinogen Homo sapiens 80-94 6086794-10 1984 Our results suggest that preoperative spironolactone therapy might decrease the responsiveness of aldosterone-producing adenomas to angiotensin II and ACTH in vitro. Spironolactone 38-52 angiotensinogen Homo sapiens 132-146 6385344-0 1984 Angiotensin II analogue infusion test in renovascular hypertension under low sodium intake and under spironolactone administration: is angiotensin II analogue infusion test useful in determining the mode of treatment? Spironolactone 101-115 angiotensinogen Homo sapiens 0-14 6385344-4 1984 Angiotensin II analogue (A II A) infusion test under spironolactone administration was more effective than under sodium depletion. Spironolactone 53-67 angiotensinogen Homo sapiens 0-14 22172779-12 2011 CONCLUSIONS: Addition of spironolactone to standard angiotensin II inhibition improved myocardial abnormalities and decreased fibrotic markers in MS. Spironolactone 25-39 angiotensinogen Homo sapiens 52-66 973876-2 1976 When spironolactone or amiloride replaced Slow K, distinct parallel increments in the levels of renin, angiotensin II, and aldosterone resulted. Spironolactone 5-19 angiotensinogen Homo sapiens 103-117 31560448-4 2020 After six months of spironolactone treatment, change in left ventricular ejection fraction (LVEF) differed by both AGT rs699 (CC, 14.6%; TC, 7.9%; TT, 2.7%; p=2.1E-26) and CYP11B2 rs1799998 (TT, 9.1%; TC, 8.7%; CC, 1.4%; p=0.0006) genotypes. Spironolactone 20-34 angiotensinogen Homo sapiens 115-118 31560448-5 2020 Multivariate linear regression showed that the AGT rs699 and CYP11B2 rs1799998 polymorphisms plus baseline serum potassium explained 71% of variability in LVEF improvement (p=0.001), 63% of variability in serum potassium increase (p=2.25E-08), and 39% of the variability in improvement in quality of life (p=2.3E-04) with spironolactone therapy. Spironolactone 322-336 angiotensinogen Homo sapiens 47-50 31560448-6 2020 These data suggest that AGT and CYP11B2 genotypes as well as baseline serum K are predictors of spironolactone response in HFrEF. Spironolactone 96-110 angiotensinogen Homo sapiens 24-27 32721806-5 2020 Current data shows that spironolactone may concurrently mitigate abnormal ACE2 expression, correct the balances membrane-attached and free circulating ACE2 and between angiotensin II and Angiotensin-(1-7) (Ang-(1-7)), suppress androgen-mediated TMPRSS2 activity, and inhibit obesity-related RAAS dysfunctions, with consequent decrease of viral priming. Spironolactone 24-38 angiotensinogen Homo sapiens 168-182 31373631-4 2019 AngII activation of MR was blocked by the MR antagonist spironolactone or eplerenone and the protein kinase C-delta (PKCdelta) inhibitor rottlerin, implicating both in the mechanism. Spironolactone 56-70 angiotensinogen Homo sapiens 0-5 31373631-8 2019 The impact of AngII on FKBP51 reporter activity and gene expression in SMCs was inhibited by spironolactone and rottlerin. Spironolactone 93-107 angiotensinogen Homo sapiens 14-19 31373631-9 2019 Finally, the AngII-induced increase in SMC number was also blocked by the MR antagonist spironolactone and the PKCdelta inhibitor rottlerin. Spironolactone 88-102 angiotensinogen Homo sapiens 13-18 20592661-5 2011 Aldosterone antagonists like spironolactone when administered concomitantly with losartan can attenuate angiotensin II-enhanced cytokine production in HF. Spironolactone 29-43 angiotensinogen Homo sapiens 104-118 18819053-7 2009 Spironolactone inhibited Ang II stimulation of aldosterone production by 80%. Spironolactone 0-14 angiotensinogen Homo sapiens 25-31 17043157-5 2006 Angiotensin II increased blood pressure (increase in systolic pressure: 13.7+/-7.5 and 15.2+/-9.4 mm Hg during placebo and spironolactone, respectively; P<0.001 for angiotensin II) and decreased renal plasma flow (-202+/-73 and -167+/-112 mL/min/1.73 kg/m(2); P<0.001 for angiotensin II effect) similarly during placebo and spironolactone. Spironolactone 123-137 angiotensinogen Homo sapiens 0-14 18347776-7 2008 However, spironolactone significantly worsened glycaemic control, plasma angiotensin II and cortisol. Spironolactone 9-23 angiotensinogen Homo sapiens 73-87 18347776-9 2008 We speculate that any tendency for the spironolactone-induced lowering of blood pressure to improve endothelial function is offset by its tendency to worsen glycaemic control and increase the levels of angiotensin II and even possibly cortisol. Spironolactone 39-53 angiotensinogen Homo sapiens 202-216 17995524-3 2007 It was shown in mesangial cells that the increased expression of TGF-beta and plasminogen activator inhibitor-1 induced by angiotensin II was suppressed by the treatment with ARB, calcium channel blocker (CCB), spironolactone or peroxisome proliferator-activated-receptor-gamma (PPAR-gamma) agonist. Spironolactone 211-225 angiotensinogen Homo sapiens 123-137 17043157-5 2006 Angiotensin II increased blood pressure (increase in systolic pressure: 13.7+/-7.5 and 15.2+/-9.4 mm Hg during placebo and spironolactone, respectively; P<0.001 for angiotensin II) and decreased renal plasma flow (-202+/-73 and -167+/-112 mL/min/1.73 kg/m(2); P<0.001 for angiotensin II effect) similarly during placebo and spironolactone. Spironolactone 330-344 angiotensinogen Homo sapiens 0-14 17043157-6 2006 Spironolactone enhanced the aldosterone response to angiotensin II (increase of 17.0+/-10.6 versus 9.0+/-5.7 ng/dL; P=0.002). Spironolactone 0-14 angiotensinogen Homo sapiens 52-66 16337046-11 2006 Spironolactone use was an independent predictor of elevated plasma angiotensin II levels. Spironolactone 0-14 angiotensinogen Homo sapiens 67-81 16337046-16 2006 Although a causal link could not be proven, an association was found between spironolactone use and active renin protein, angiotensin II and aldosterone levels, suggesting that escape from ACE is mainly caused by a feedback mechanism. Spironolactone 77-91 angiotensinogen Homo sapiens 122-136 15718497-10 2005 Angiotensin II activation of MR-mediated gene expression is inhibited by both the AT1 receptor blocker losartan and by spironolactone, but not by aldosterone synthase inhibition. Spironolactone 119-133 angiotensinogen Homo sapiens 0-14 16081869-4 2005 This effect of a combination of Aldo and Ang II was markedly inhibited by a selective AT1 receptor blocker, olmesartan, a mineralocorticoid receptor antagonist, spironolactone, an MEK inhibitor, PD98059, or an EGF receptor tyrosine kinase inhibitor, AG1478. Spironolactone 161-175 angiotensinogen Homo sapiens 41-47 15749161-4 2005 In this article, several angiotensin II AT(1) receptor antagonists (candesartan, E3174, eprosartan, irbesartan and losartan) and aldosterone receptor antagonists (canrenoic acid and spironolactone) that directly modulate the activity of the voltage-dependent K(+) channels are reviewed; the effects of these antagonists might be useful in the prevention and treatment of cardiac arrhythmias. Spironolactone 182-196 angiotensinogen Homo sapiens 25-39